NCT00832572 - Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Coronary Artery DiseasePainPeripheral Nervous System DiseasesPolyneuropathy

Interventions

DRUG

Ranolazine

Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).

DRUG

Placebo

Placebo to match ranolazine administered twice a day for 6 weeks

Trial Locations (1)

Cardiovascular Institute of the South Clinical Research Corporation, Houma